ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

laboratorios hipra s.a. - v živo vidni goveja dihal syncytial virus (brsv), sev lym-56 - immunologicals za bovidae, govedo, Živo, virusna cepiva, goveje dihal syncytial virus (brsv) - govedo - aktivno imunizacijo goveda (za zmanjšanje virus prelivanje in dihal, klinične znake, ki jih povzročajo goveja dihal syncytial virus okužbe.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

bayer animal health gmbh - iron(iii) ion, toltrazuril - toltrazuril, kombinacije - prašiči (pujski) - za sočasnem preprečevanju kliničnih znakov coccidiosis (kot so driska) v novorojenčku pujski na kmetijah, s potrjeno zgodovino coccidiosis zaradi cystoisospora suis, in preprečevanje pomanjkanja železa anemija.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

csl behring gmbh - lonoktokog alfa - hemofilija a - antihemoragije - zdravljenje in profilaksa krvavitve pri bolnikih s hemofilijo a (prirojeno pomanjkanje faktorja viii). afstyla se lahko uporablja za vse starostne skupine.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pliva ljubljana d.o.o., ljubljana - azitromicin - prašek za raztopino za infundiranje - azitromicin 500 mg / 1 viala - azitromicin

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa - hemofilija a - koagulacija faktor viii - zdravljenje in profilaksa krvavitve pri bolnikih s hemofilijo a (prirojeno pomanjkanje faktorja viii). novoeight se lahko uporablja za vse starostne skupine.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

boehringer ingelheim animal health france scs 29 -

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle cell - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.